This study seeks to investigate potential cardioprotection of Danlou
Tablets in patients undergoing PCI with non-ST elevation
acute coronary syndrome (NSTE-ACS). 219 patients with NSTE-ACS were randomised to
Danlou Tablet pretreatment (n = 109) or placebo (n = 110). No patients received
statins prior to PCI and all patients were given
atorvastatin (10 mg/day) after procedure. The main endpoint was the composite incidence of
major adverse cardiac events (MACEs) within 30 days after PCI. The proportion of patients with elevated levels of
cTn I>5 × 99% of upper reference limit was significantly lower in the
Danlou Tablet group at 8 h (22.0% versus 34.5%, p = 0.04) and 24 h (23.9% versus 38.2%, p = 0.02) after PCI. The 30-day MACEs occurred in 22.0% of the
Danlou Tablet group and 33.6% in the placebo group (p = 0.06). The incidence of
MACE at 90-day follow-up was significantly decreased in the
Danlou Tablet group compared to the placebo group (23.9% versus 37.3%, p = 0.03). The difference between the groups at 90 days was the incidence of nonfatal
myocardial infarction (22% versus 34.5%, p = 0.04). These findings might support that treatment with
Danlou Tablet could reduce the incidence of periprocedural
myocardial infarction in patients with ACS undergoing PCI.